Rafael Amado - 30 Dec 2022 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President, Head of Global Oncology Research and Development
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Issuer symbol
ZLAB
Transactions as of
30 Dec 2022
Net transactions value
$0
Form type
4
Filing time
03 Jan 2023, 15:10:15 UTC
Previous filing
11 Oct 2022
Next filing
05 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZLAB American Depositary Shares Award $0 +126,000 $0.000000 126,000 30 Dec 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Stock Options (Right to Buy) Award $0 +183,700 $0.000000 183,700 30 Dec 2022 American Depositary Shares 183,700 $30.70 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2 The Stock Options vest in equal annual installments over five years beginning on 12/30/2023, the first anniversary of the date of grant.

Remarks:

President, Head of Global Oncology Research and Development